Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent

References

• Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135(5):3172–3177.
   PubMed Web of Science ®Google Scholar
• Renauld JC, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci U S A. 1992;89(12):5690–5694. doi:10.1073/pnas.89.12.5690
   Web of Science ®Google Scholar
• Goodwin RG, Friend D, Ziegler SF, et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell. 1990;60(6):941–951. doi:10.1016/0092-8674(90)90342-C
   Web of Science ®Google Scholar
• Mosley B, Beckmann MP, March CJ, et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 1989;59(2):335–348. doi:10.1016/0092-8674(89)90295-X
   Web of Science ®Google Scholar
• Tavernier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF. Cell. 1991;66(6):1175–1184. doi:10.1016/0092-8674(91)90040-6
   PubMed Web of Science ®Google Scholar
• Orlando S, Sironi M, Bianchi G, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem. 1997;272(50):31764–31769. doi:10.1074/jbc.272.50.31764
   Web of Science ®Google Scholar
• Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol. 2000;164(10):5277–5286. doi:10.4049/jimmunol.164.10.5277
   Web of Science ®Google Scholar
• Mülberg J, Schooltink H, Stoyan T, et al. The soluble interleukin‐6 receptor is generated by shedding. Eur J Immunol. 1993;23(2):473–480. doi:10.1002/eji.1830230226
   Web of Science ®Google Scholar
• Horiuchi S, Koyanagiu Y, Zhouu Y, et al. Soluble interleukin‐6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24(8):1945–1948. doi:10.1002/eji.1830240837
   Web of Science ®Google Scholar
• Schumacher N, Meyer D, Mauermann A, et al. Shedding of endogenous interleukin-6 receptor (il-6r) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6r isoform localizes to circulating microvesicles. J Biol Chem. 2015;290(43):26059–26071. doi:10.1074/jbc.M115.649509
   PubMed Web of Science ®Google Scholar
• Hawari FI, Rouhani FN, Cui X, et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A. 2004;101(5):1297–1302. doi:10.1073/pnas.0307981100
   Web of Science ®Google Scholar
• Viaud S, Terme M, Flament C, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα. Pockley G ed. PLoS One. 2009;4(3):e4942. doi:10.1371/journal.pone.0004942
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Smith MF, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol. 1994;153(10):4766–4774.
   Web of Science ®Google Scholar
• Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol. 2003;171(12):6814–6819. doi:10.4049/jimmunol.171.12.6814
   PubMed Web of Science ®Google Scholar
• Zegeye MM, Lindkvist M, Fälker K, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018;16(1):55. doi:10.1186/s12964-018-0268-4
   PubMed Web of Science ®Google Scholar
• Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370(6486):218–220. doi:10.1038/370218a0
   Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385(6618):729–733. doi:10.1038/385729a0
   PubMed Web of Science ®Google Scholar
• Moss ML, Jin S-LC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature. 1997;385(6618):733–736. doi:10.1038/385733a0
   PubMed Web of Science ®Google Scholar
• Zunke F, Rose-John S. The shedding protease ADAM17: physiology and pathophysiology. Biochim Biophys Acta. 2017;1864(11):2059–2070. doi:10.1016/J.BBAMCR.2017.07.001
   Web of Science ®Google Scholar
• Wolf J, Waetzig GH, Reinheimer TM, Scheller J, Rose-John S, Garbers C. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing. Biochem Biophys Res Commun. 2016;470(4):870–876. doi:10.1016/j.bbrc.2016.01.127
   Web of Science ®Google Scholar
• Heink S, Yogev N, Garbers C, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2016;18(1):74–85. doi:10.1038/ni.3632
   PubMed Web of Science ®Google Scholar
• Vranjkovic A, Crawley AM, Gee K, Kumar A, Angel JB. IL-7 decreases IL-7 receptor (CD127) expression and induces the shedding of CD127 by human CD8+ T cells. Int Immunol. 2007;19(12):1329–1339. doi:10.1093/intimm/dxm102
   Web of Science ®Google Scholar
• Blom-Potar M-C, Bugault F, Lambotte O, Delfraissy J-F, Thèze J. Soluble IL-7Ralpha (sCD127) and measurement of IL-7 in the plasma of HIV patients. J Acquir Immune Defic Syndr. 2009;51(1):104–105. doi:10.1097/QAI.0b013e31819d8a20
   Web of Science ®Google Scholar
• Crawley AM, Faucher S, Angel JB. Soluble IL-7Rα (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010;184(9):4679–4687. doi:10.4049/jimmunol.0903758
   Web of Science ®Google Scholar
• Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3(4):269–279. doi:10.1038/nri1052
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Douek DC, McFarland RD, Koup RA. IL-7, the thymus, and naiïve T cells. Adv Exp Med Biol. 2002;512:81–90. doi:10.1007/978-1-4615-0757-4_11
   Web of Science ®Google Scholar
• Marrack P, Kappler J. Control of T cell viability. Annu Rev Immunol. 2004;22(1):765–787. doi:10.1146/annurev.immunol.22.012703.104554
   Web of Science ®Google Scholar
• Khaled AR, Durum SK. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol. 2002;2(11):817–830. doi:10.1038/nri931
   PubMed Web of Science ®Google Scholar
• Zaunders JJ, Lévy Y, Seddiki N. Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses. Cytokine Growth Factor Rev. 2014;25(4):391–401. doi:10.1016/J.CYTOGFR.2014.07.012
   Web of Science ®Google Scholar
• Madrigal-Estebas L, McManus R, Byrne B, et al. Human small intestinal epithelial cells secrete interleukin-7 and differentially express two different interleukin-7 mRNA transcripts: implications for extrathymic T-cell differentiation. Hum Immunol. 1997;58(2):83–90. doi:10.1016/S0198-8859(97)00230-9
   Web of Science ®Google Scholar
• Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest. 1995;95(6):2945–2953. doi:10.1172/JCI118002
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Kelly AM, Traynor O, et al. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development. Cytokine. 2001;14(3):143–151. doi:10.1006/cyto.2001.0852
   Web of Science ®Google Scholar
• G-r JC, Olsson C, Palacios R. Interleukin (IL1 to IL7) gene expression in fetal liver and bone marrow stromal clones: cytokine-mediated positive and negative regulation. Exp Hematol. 1992;20(8):986–990.
   Web of Science ®Google Scholar
• Heufler C, Topar G, Grasseger A, et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med. 1993;178(3):1109–1114. doi:10.1084/jem.178.3.1109
   Web of Science ®Google Scholar
• de Saint-vis B, Fugier-Vivier I, Massacrier C, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998;160(4):1666–1676.
   Web of Science ®Google Scholar
• Sorg RV, Mclellan AD, Hock BD, Fearnley DB, Hart DNJ. Human dendritic cells express functional interleukin-7. Immunobiology. 1998;198(5):514–526. doi:10.1016/S0171-2985(98)80075-2
   Web of Science ®Google Scholar
• Kröncke R, Loppnow H, Flad H-D, Gerdes J. Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction. Eur J Immunol. 1996;26(10):2541–2544. doi:10.1002/eji.1830261040
   Web of Science ®Google Scholar
• Guimond M, Veenstra RG, Grindler DJ, et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol. 2009;10(2):149–157. doi:10.1038/ni.1695
   Web of Science ®Google Scholar
• Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993;262(5141):1877–1880. doi:10.1126/science.8266077
   PubMed Web of Science ®Google Scholar
• Jiang Q, Wen QL, Aiello FB, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005;16(4–5):513–533. doi:10.1016/j.cytogfr.2005.05.004
   PubMed Web of Science ®Google Scholar
• Spolski R, Gromer D, Leonard WJ. The γc family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response. F1000Research. 2017;6:1872. doi:10.12688/f1000research.12202.1
   Google Scholar
• Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007;7(2):144–154. doi:10.1038/nri2023
   PubMed Web of Science ®Google Scholar
• Park LS, Martin U, Garka K, et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med. 2000;192(5):659–669. doi:10.1084/jem.192.5.659
   PubMed Web of Science ®Google Scholar
• McElroy CA, Holland PJ, Zhao P, et al. Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A. 2012;109(7):2503–2508. doi:10.1073/pnas.1116582109
   Web of Science ®Google Scholar
• Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol. 2008;5(2):79–89. doi:10.1038/cmi.2008.10
   PubMed Web of Science ®Google Scholar
• Jiang Q, Li WQ, Aiello FB, Klarmann KD, Keller JR, Durum SK. Retroviral transduction of IL-7Rα into IL-7Rα-/- bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia. Gene Ther. 2005;12(24):1761–1768. doi:10.1038/sj.gt.3302558
   Web of Science ®Google Scholar
• Jiang Q, Li WQ, Hofmeister RR, et al. Distinct regions of the interleukin-7 receptor regulate different bcl2 family members. Mol Cell Biol. 2004;24(14):6501–6513. doi:10.1128/mcb.24.14.6501-6513.2004
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR, Cowling RJ. Interleukin‐7 induces the association of phosphatidylinositol 3‐kinase with the α chain of the interleukin‐7 receptor. Eur J Immunol. 1994;24(9):2168–2174. doi:10.1002/eji.1830240935
   Web of Science ®Google Scholar
• MacKall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011;11(5):330–342. doi:10.1038/nri2970
   PubMed Web of Science ®Google Scholar
• Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol. 2011;12(6):478–484. doi:10.1038/ni.2018
   PubMed Web of Science ®Google Scholar
• Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99(11):3892–3904. doi:10.1182/blood.V99.11.3892
   PubMed Web of Science ®Google Scholar
• Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671–676. doi:10.1038/nature02067
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol. 2001;167(12):6869–6876. doi:10.4049/jimmunol.167.12.6869
   Web of Science ®Google Scholar
• Lee LF, Axtell R, Tu GH, et al. IL-7 promotes TH1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med. 2011;3(93):93ra68–93ra68. doi:10.1126/scitranslmed.3002400
   PubMed Web of Science ®Google Scholar
• Lee L-F, Logronio K, Tu GH, et al. Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A. 2012;109(31):12674–12679. doi:10.1073/pnas.1203795109
   Web of Science ®Google Scholar
• Park J-H, Yu Q, Erman B, et al. Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004;21(2):289–302. doi:10.1016/j.immuni.2004.07.016
   Web of Science ®Google Scholar
• Teutsch SM, Booth DR, Bennetts BH, Heard RNSN, Stewart GJ. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-a gene and their associations with multiple sclerosis. Eur J Hum Genet. 2003;11(7):509–515. doi:10.1038/sj.ejhg.5200994
   PubMed Web of Science ®Google Scholar
• Korte A, Köchling J, Badiali L, et al. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Rα chain encoding two truncated receptor proteins in relapsed childhood all. Cytokine. 2000;12(11):1597–1608. doi:10.1006/cyto.2000.0777
   Web of Science ®Google Scholar
• Rane L, Vudattu N, Bourcier K, et al. Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Rα) in peripheral blood from patients with multiple sclerosis (MS). J Neuroimmunol. 2010;222(1–2):82–86. doi:10.1016/j.jneuroim.2010.02.014
   Web of Science ®Google Scholar
• Rose T, Lambotte O, Pallier C, Delfraissy J-F, Colle J-H. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009;182(12):7389–7397. doi:10.4049/jimmunol.0900190
   Web of Science ®Google Scholar
• Lundström W, Highfill S, Walsh STR, et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A. 2013;110(19):E1761–1770. doi:10.1073/pnas.1222303110
   PubMed Web of Science ®Google Scholar
• Côté S, Matte J, Sad S, Angel JB, Crawley AM. Complexed soluble IL-7 receptor α and IL-7 increase IL-7-mediated proliferation and viability of CD8+ T-cells in vitro. Cell Immunol. 2015;293(2):122–125. doi:10.1016/j.cellimm.2015.01.001
   Web of Science ®Google Scholar
• Aloufi N The role of sCD127 in mediating IL-7 function on T cell homeostasis in vivo, PhD thesis, University of Ottawa, 2020. Available from: https://ruor.uottawa.ca/bitstream/10393/41089/1/Aloufi_Nawaf_2020_Thesis.pdf. Accessed February 26, 2021.
   Google Scholar
• Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851–862. doi:10.1056/NEJMoa073493
   PubMed Web of Science ®Google Scholar
• Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39(7):857–864. doi:10.1038/ng2068
   PubMed Web of Science ®Google Scholar
• Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-α: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37(5):485–491. doi:10.1038/sj.bmt.1705277
   PubMed Web of Science ®Google Scholar
• Shamim Z, Ryder LP, Christensen IJ, et al. Prognostic significance of interleukin-7 receptor-α gene polymorphisms in allogeneic stem-cell transplantation: a confirmatory study. Transplantation. 2011;91(7):1. doi:10.1097/TP.0b013e31820f08b2
   Web of Science ®Google Scholar
• Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor α chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007;39(9):1083–1091. doi:10.1038/ng2103
   PubMed Web of Science ®Google Scholar
• Jäger J, Schulze C, Rö Sner S, Martin R. IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. Genes Immun. 2013;14(7):453–461. doi:10.1038/gene.2013.40
   Web of Science ®Google Scholar
• Galarza-Muñoz G, Briggs FBS, Evsyukova I, et al. Human epistatic interaction controls IL7R splicing and increases multiple sclerosis risk. Cell. 2017;169(1):72–84.e13. doi:10.1016/j.cell.2017.03.007
   PubMed Web of Science ®Google Scholar
• Masuda S, Das R, Cheng H, Hurt E, Dorman N, Reed R. Recruitment of the human TREX complex to mRNA during splicing. Genes Dev. 2005;19(13):1512–1517. doi:10.1101/gad.1302205
   PubMed Web of Science ®Google Scholar
• Luo MJ, Zhou Z, Magni K, et al. Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and aly. Nature. 2001;413(6856):644–647. doi:10.1038/35098106
   PubMed Web of Science ®Google Scholar
• Shen J, Zhang L, Zhao R. Biochemical characterization of the ATPase and helicase activity of UAP56, an essential pre-mRNA splicing and mRNA export factor. J Biol Chem. 2007;282(31):22544–22550. doi:10.1074/jbc.M702304200
   PubMed Web of Science ®Google Scholar
• Shen H, Zheng X, Shen J, Zhang L, Zhao R, Green MR. Distinct activities of the DExD/H-box splicing factor hUAP56 facilitate stepwise assembly of the spliceosome. Genes Dev. 2008;22(13):1796–1803. doi:10.1101/gad.1657308
   Web of Science ®Google Scholar
• Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520–532. doi:10.1016/S1474-4422(10)70064-8
   PubMed Web of Science ®Google Scholar
• Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(191):1–10. doi:10.22074/cellj.2016.4867
   Google Scholar
• Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353–1360. doi:10.1038/ng.2770
   PubMed Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–219. doi:10.1038/nature10251
   PubMed Web of Science ®Google Scholar
• Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part II. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e277. doi:10.1212/NXI.0000000000000277
   Web of Science ®Google Scholar
• Liu H, Huang J, Dou M, et al. Variants in the IL7RA gene confer susceptibility to multiple sclerosis in Caucasians: evidence based on 9734 cases and 10436 controls. Sci Rep. 2017;7(1):1–10. doi:10.1038/s41598-017-01345-8
   PubMed Web of Science ®Google Scholar
• Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007;39(9):1108–1113. doi:10.1038/ng2106
   PubMed Web of Science ®Google Scholar
• Alcina A, Fedetz M, Ndagire D, et al. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. Tissue Antigens. 2008;72(2):158–161. doi:10.1111/j.1399-0039.2008.01075.x
   PubMedGoogle Scholar
• Sombekke MH, Van Der Voort LF, Kragt JJ, et al. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis. Mult Scler J. 2011;17(8):922–930. doi:10.1177/1352458511402411
   Web of Science ®Google Scholar
• Stanković A, Dinčić E, Ristić S, et al. Interleukin 7 receptor alpha polymorphism rs6897932 and susceptibility to multiple sclerosis in the Western Balkans. Mult Scler. 2010;16(5):533–536. doi:10.1177/1352458509360548
   Web of Science ®Google Scholar
• Broux B, Hellings N, Venken K, et al. Haplotype 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants. Genes Immun. 2010;11(4):326–333. doi:10.1038/gene.2009.106
   Web of Science ®Google Scholar
• Rubio JP, Stankovich J, Field J, et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 2008;9(7):624–630. doi:10.1038/gene.2008.59
   PubMed Web of Science ®Google Scholar
• O’Doherty C, Kantarci O, Vandenbroeck K. IL7RA polymorphisms and susceptibility to multiple sclerosis. N Engl J Med. 2008;358(7):753–754. doi:10.1056/NEJMc0707553
   PubMed Web of Science ®Google Scholar
• Weber F, Fontaine B, Cournu-Rebeix I, et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 2008;9(3):259–263. doi:10.1038/gene.2008.14
   PubMed Web of Science ®Google Scholar
• Kreft KL, Verbraak E, Wierenga-Wolf AF, et al. Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients. Genes Immun. 2012;13(7):587–592. doi:10.1038/gene.2012.34
   Web of Science ®Google Scholar
• Kim JY, Cheong HS, Kim HJ, Kim LH, Namgoong S, Shin HD. Association analysis of IL7R polymorphisms with inflammatory demyelinating diseases. Mol Med Rep. 2014;9(2):737–743. doi:10.3892/mmr.2013.1863
   Web of Science ®Google Scholar
• Fang L, Isobe N, Yoshimura S, et al. Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians. Neurology. 2011;76(24):2125–2127. doi:10.1212/WNL.0b013e31821f466c
   Web of Science ®Google Scholar
• Sayad A, Omrani MD, Solgi G, et al. Interleukin 7 receptor alpha gene variants are correlated with gene expression in patients with relapsing-remitting multiple sclerosis. Iran J Allergy Asthma Immunol. 2017;16(4):338–346.
   Web of Science ®Google Scholar
• Taheri M, Sayad A. Investigating the exon 6 sequence changes of interleukin 7 receptor A (IL7RA) gene in patients with relapsing-remitting multiple sclerosis. Hum Antibodies. 2017;26(2):43–48. doi:10.3233/HAB-170320
   Google Scholar
• Majdinasab N, Hosseini Behbahani M, Galehdari H, Mohaghegh M. Association of interleukin 7 receptor gene polymorphism rs6897932 with multiple sclerosis patients in Khuzestan. Iran J Neurol. 2014;13(3):168–171.
   Google Scholar
• Pandit L, Ban M, Sawcer S, et al. Evaluation of the established non-MHC multiple sclerosis loci in an Indian population. Mult Scler J. 2011;17(2):139–143. doi:10.1177/1352458510384011
   Web of Science ®Google Scholar
• Zhuang JC, Wu L, Qian MZ, et al. Variants of interleukin-7/interleukin-7 receptor alpha are associated with both neuromyelitis optica and multiple sclerosis among Chinese han population in southeastern China. Chin Med J. 2015;128(22):3062–3068. doi:10.4103/0366-6999.169093
   Web of Science ®Google Scholar
• Ibayyan L, Zaza R, Dahbour S, et al. The promoter SNP, but not the alternative splicing SNP, is linked to multiple sclerosis among Jordanian patients. J Mol Neurosci. 2014;52(4):467–472. doi:10.1007/s12031-013-0151-0
   Web of Science ®Google Scholar
• Haj MS, Nikravesh A, Kakhki MP, Rakhshi N. Association study of four polymorphisms in the interleukin-7 receptor alpha gene with multiple sclerosis in Eastern Iran. Iran J Basic Med Sci. 2015;18(6):593–598.
   PubMed Web of Science ®Google Scholar
• Tavakolpour S. Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2016;8:66–73. doi:10.1016/j.msard.2016.05.001
   Web of Science ®Google Scholar
• Wu S, Liu Q, Zhu JM, Wang MR, Li J, Sun MG. Association between the IL7R T244I polymorphism and multiple sclerosis risk: a meta analysis. Neurol Sci. 2016;37(9):1467–1474. doi:10.1007/s10072-016-2608-8
   Web of Science ®Google Scholar
• Sahami-Fard MH, Mozhdeh M, Izadpanah F, Kashani HH, Nezhadi A. Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis. J Neuroimmunol. 2020;341:577166. doi:10.1016/j.jneuroim.2020.577166
   Web of Science ®Google Scholar
• Alvarenga RMP, Araújo ACRDAE, Nascimento ACB. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease? Mult Scler Relat Disord. 2020;42:102082. doi:10.1016/j.msard.2020.102082
   Web of Science ®Google Scholar
• Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler J. 2020;26(5):561–567. doi:10.1177/1352458519887328
   Web of Science ®Google Scholar
• Kulakova OG, Bashinskaya VV, Tsareva EY, Boyko AN, Favorova OO, Gusev EI. Association analysis of cytokine receptors’ genes polymorphisms with clinical features of multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(SpecialIssue 10):10–15. doi:10.17116/jnevro201611610210-15
   Google Scholar
• Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun. 2009;32(2):110–115. doi:10.1016/j.jaut.2009.01.002
   PubMed Web of Science ®Google Scholar
• Traboulsee AL, Bernales CQ, Ross JP, Lee JD, Sadovnick AD, Vilariño-Güell C. Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression. Neurogenetics. 2014;15(3):165–169. doi:10.1007/s10048-014-0403-3
   Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi:10.1212/WNL.0000000000001729
   PubMed Web of Science ®Google Scholar
• Kim S-H, Mealy MA, Levy M, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089–e2099. doi:10.1212/WNL.0000000000006574
   PubMed Web of Science ®Google Scholar
• Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol NeuroInflamm. 2016;3(3):e225. doi:10.1212/NXI.0000000000000225
   Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834–1849. doi:10.1093/brain/aws109
   PubMed Web of Science ®Google Scholar
• Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256(1):35–44. doi:10.1007/s00415-009-0009-0
   Web of Science ®Google Scholar
• Brill L, Lavon I, Vaknin-Dembinsky A. Reduced expression of the IL7Ra signaling pathway in neuromyelitis optica. J Neuroimmunol. 2018;324(May):81–89. doi:10.1016/j.jneuroim.2018.08.011
   Web of Science ®Google Scholar
• Dai Y, Li J, Zhong X, et al. IL2RA allele increases risk of neuromyelitis optica in Southern Han Chinese. Can J Neurol Sci. 2013;40(6):832–835. doi:10.1017/S0317167100015973
   PubMed Web of Science ®Google Scholar
• Sinha S, Singh J, Jindal SK. Association of interleukin 7 receptor (rs1494555 and rs6897932) gene polymorphisms with asthma in a north Indian population. Allergy Rhinol. 2015;6(3):168–176. doi:10.2500/ar.2015.6.0137
   PubMed Web of Science ®Google Scholar
• Santiago JL, Alizadeh BZ, Martínez A, et al. Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia. 2008;51(9):1653–1658. doi:10.1007/s00125-008-1070-4
   Web of Science ®Google Scholar
• Heron M, Grutters JC, van Moorsel CHM, et al. Variation in IL7R predisposes to sarcoid inflammation. Genes Immun. 2009;10(7):647–653. doi:10.1038/gene.2009.55
   Web of Science ®Google Scholar
• O’Doherty C, Alloza I, Rooney M, Vandenbroeck K. IL7RA polymorphisms and chronic inflammatory arthropathies. Tissue Antigens. 2009;74(5):429–431. doi:10.1111/j.1399-0039.2009.01342.x
   PubMedGoogle Scholar
• Wang XS, Wen PF, Zhang M, et al. Interleukin-7 receptor single nucleotide polymorphism rs6897932 (C/T) and the susceptibility to systemic lupus erythematosus. Inflammation. 2014;37(2):615–620. doi:10.1007/s10753-013-9777-x
   Web of Science ®Google Scholar
• Monti P, Brigatti C, Krasmann M, Ziegler AG, Bonifacio E. Concentration and activity of the soluble form of the interleukin-7 receptor α in type 1 diabetes identifies an interplay between hyperglycemia and immune function. Diabetes. 2013;62(7):2500–2508. doi:10.2337/db12-1726
   Web of Science ®Google Scholar
• Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–384. doi:10.1182/blood-2014-01-514752
   PubMed Web of Science ®Google Scholar
• Kielsen K, Shamim Z, Thiant S, et al. Soluble interleukin-7 receptor levels and risk of acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Clin Immunol. 2018;187:26–32. doi:10.1016/j.clim.2017.08.015
   PubMed Web of Science ®Google Scholar
• Shamim Z, Spellman S, Haagenson M, et al. Polymorphism in the interleukin-7 receptor-alpha and outcome after allogeneic hematopoietic cell transplantation with matched unrelated donor. Scand J Immunol. 2013;78(2):214–220. doi:10.1111/sji.12077
   PubMed Web of Science ®Google Scholar
• Vitiello GAF, Losi Guembarovski R, Amarante MK, Ceribelli JR, Carmelo ECB, Watanabe MAE. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups. Cytokine. 2018;103:121–126. doi:10.1016/j.cyto.2017.09.019
   PubMed Web of Science ®Google Scholar
• Collina F, Di Bonito M, Li Bergolis V, et al. Prognostic value of cancer stem cells markers in triple-negative breast cancer. Biomed Res Int. 2015;2015:2015. doi:10.1155/2015/158682
   Web of Science ®Google Scholar
• Sun D-P, Wang L, Ding C-Y. Investigating factors associated with thymic regeneration after chemotherapy in patients with lymphoma. Front Immunol. 2016;7(DEC):654. doi:10.3389/fimmu.2016.00654
   Web of Science ®Google Scholar
• Hartling HJ, Jespersen S, Gaardbo JC, et al. Reduced IL-7R T cell expression and increased plasma sCD127 in late presenting HIV-infected individuals. J Acquir Immune Defic Syndr. 2017;74(1):81–90. doi:10.1097/QAI.0000000000001153
   Web of Science ®Google Scholar
• Resino S, Navarrete-Muñoz MA, Blanco J, et al. IL7RA rs6897932 polymorphism is associated with better CD4+ T-cell recovery in HIV infected patients starting combination antiretroviral therapy. Biomolecules. 2019;9(6):233. doi:10.3390/biom9060233
   Web of Science ®Google Scholar
• Carini C, McLane MF, Mayer KH, Essex M. Dysregulation of interleukin‐7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur J Immunol. 1994;24(12):2927–2934. doi:10.1002/eji.1830241202
   Web of Science ®Google Scholar
• Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis. 2010;202(8):1254–1264. doi:10.1086/656369
   Web of Science ®Google Scholar
• Hartling HJ, Thørner LW, Erikstrup C, et al. Polymorphism in interleukin-7 receptor α gene is associated with faster CD4+ T-cell recovery after initiation of combination antiretroviral therapy. AIDS. 2014;28(12):1739–1748. doi:10.1097/QAD.0000000000000354
   Web of Science ®Google Scholar
• Rajasuriar R, Booth DR, Gouillou M, et al. The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes Immun. 2012;13(1):83–93. doi:10.1038/gene.2011.65
   Web of Science ®Google Scholar
• Hartling HJ, Thørner LW, Erikstrup C, et al. Polymorphisms in the interleukin-7 receptor α gene and mortality in untreated HIV-infected individuals. AIDS. 2013;27(10):1615–1620. doi:10.1097/QAD.0b013e3283606c2d
   Web of Science ®Google Scholar
• Medrano LM, Jiménez JL, Jiménez-Sousa MA, et al. IL7RA polymorphisms are not associated with AIDS progression. Eur J Clin Invest. 2017;47(10):719–727. doi:10.1111/eci.12797
   Web of Science ®Google Scholar
• Maier I, Wu GY. Hepatitis C and HIV co-infection: a review. World J Gastroenterol. 2002;8(4):577–579. doi:10.3748/wjg.v8.i4.577
   Web of Science ®Google Scholar
• Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, et al. The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: repeated measurements design. PLoS One. 2018;13(5):e0197115. doi:10.1371/journal.pone.0197115
   Web of Science ®Google Scholar
• Guzmán-Fulgencio M, Berenguer J, Jiménez-Sousa MA, et al. Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study. J Transl Med. 2015;13:206. doi:10.1186/s12967-015-0577-y
   Web of Science ®Google Scholar
• Rethi B, Fluur C, Atlas A, et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS. 2005;19(18):2077–2086. doi:10.1097/01.aids.0000189848.75699.0f
   Web of Science ®Google Scholar
• MacPherson PA, Fex C, Sanchez-Dardon J, Hawley-Foss N, Angel JB. Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(5):454–457. doi:10.1097/00042560-200112150-00008
   Web of Science ®Google Scholar
• Paiardini M, Cervasi B, Albrecht H, et al. Loss of CD127 expression defines an expansion of effector CD8 + T cells in HIV-infected individuals. J Immunol. 2005;174(5):2900–2909. doi:10.4049/jimmunol.174.5.2900
   Web of Science ®Google Scholar
• Faller E, Kakal J, Kumar R, MacPherson P. IL-7 and the HIV Tat protein act synergistically to down-regulate CD127 expression on CD8 T cells. Int Immunol. 2009;21(3):203–216. doi:10.1093/intimm/dxn140
   Web of Science ®Google Scholar
• Mouillaux J, Allam C, Rimmelé T, et al. Regulation of soluble CD127 protein release and corresponding transcripts expression in T lymphocytes from septic shock patients. Intensive Care Med Exp. 2019;7(1):3. doi:10.1186/s40635-018-0220-3
   Web of Science ®Google Scholar
• Peronnet E, Mouillaux J, Monneret G, et al. Elevated soluble IL-7 receptor concentration in non-survivor ICU patients. Intensive Care Med. 2016;42(10):1639–1640. doi:10.1007/s00134-016-4445-x
   Web of Science ®Google Scholar
• Delwarde B, Peronnet E, Venet F, et al. Low interleukin-7 receptor messenger RNA expression is independently associated with day 28 mortality in septic shock patients. Crit Care Med. 2018;46(11):1739–1746. doi:10.1097/CCM.0000000000003281
   Web of Science ®Google Scholar
• Demaret J, Villars-Méchin A, Lepape A, et al. Elevated plasmatic level of soluble IL-7 receptor is associated with increased mortality in septic shock patients. Intensive Care Med. 2014;40(8):1089–1096. doi:10.1007/s00134-014-3346-0
   Web of Science ®Google Scholar
• Lundtoft C, Afum-Adjei Awuah A, Rimpler J, et al. Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis. PLoS Pathog. 2017;13(6):e1006425. doi:10.1371/journal.ppat.1006425
   Web of Science ®Google Scholar
• Rane L, Rahman S, Magalhaes I, et al. Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue. Genes Immun. 2011;12(7):513–522. doi:10.1038/gene.2011.29
   Web of Science ®Google Scholar
• Badot V, Luijten RKMAC, van Roon JA, et al. Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(3):453–456. doi:10.1136/annrheumdis-2012-202364
   Web of Science ®Google Scholar
• Chi S, Xue J, Li F, et al. Correlation of serum soluble interleukin-7 receptor and anti-C1q antibody in patients with systemic lupus erythematosus. Autoimmune Dis. 2016;2016:1–11. doi:10.1155/2016/8252605
   Google Scholar
• Badot V, Durez P, Van den Eynde BJ, Nzeusseu-Toukap A, Houssiau FA, Lauwerys BR. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. J Cell Mol Med. 2011;15(11):2335–2342. doi:10.1111/j.1582-4934.2010.01228.x
   Web of Science ®Google Scholar
• Blokland SLM, Hillen MR, Kruize AA, et al. Increased CCL25 and T helper cells expressing CCR9 in the salivary glands of patients with primary sjögren’s syndrome: potential new axis in lymphoid neogenesis. Arthritis Rheumatol. 2017;69(10):2038–2051. doi:10.1002/art.40182
   PubMed Web of Science ®Google Scholar
• Torrealba MP, Manfrere KC, Miyashiro DR, et al. Chronic activation profile of circulating CD8+ T cells in Sézary syndrome. Oncotarget. 2018;9(3):3497–3506. doi:10.18632/oncotarget.23334
   PubMedGoogle Scholar
• Leligdowicz A, Matthay MA. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit Care. 2019;23(1):80. doi:10.1186/s13054-019-2372-2
   PubMed Web of Science ®Google Scholar
• Bedri SK, Fink K, Manouchehrinia A, et al. Multiple sclerosis treatment effects on plasma cytokine receptor levels. Clin Immunol. 2018;187:15–25. doi:10.1016/j.clim.2017.08.023
   PubMed Web of Science ®Google Scholar
• Poiret T, Rane L, Remberger M, et al. Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. BMC Immunol. 2014;15(1):25. doi:10.1186/1471-2172-15-25
   Web of Science ®Google Scholar
• Rose-John S. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Ther. 2017;102(4):591–598. doi:10.1002/cpt.782
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist. Int J Antimicrob Agents. 2020;55(2020):105954–105960. doi:10.1016/j.ijantimicag.2020.105954
   Web of Science ®Google Scholar
• Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides tocilizumab? SGP130Fc. Cytokine X. 2020;2(2):100029. doi:10.1016/j.cytox.2020.100029
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-α inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22(3):557–565. doi:10.1177/039463200902200301
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Gulli R, Span F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11(1):1–5. doi:10.1517/14740338.2012.630388
   PubMed Web of Science ®Google Scholar
• Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29–37. doi:10.1016/j.semarthrit.2017.02.001
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Belinchón I, De-la-cueva P, Izu R, Luelmo J, Ruiz-Villaverde R. Expert recommendations on treating psoriasis in special circumstances. Actas Dermosifiliogr. 2015;106(4):292–309. doi:10.1016/j.adengl.2015.03.019
   Google Scholar
• Andersson Å, Srivastava MK, Harris-White M, et al. Role of CXCR3 ligands in IL-7/IL-7Rα-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res. 2011;17(11):3660–3672. doi:10.1158/1078-0432.CCR-10-3346
   Web of Science ®Google Scholar